Pulmocide Ltd

Industry · 9 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory IPA	Phase 3	2022-06-14
Completed	A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in L Pulmonary Aspergillosis	Phase 2	2021-11-19
Terminated	The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. Aspergillosis, Lung Transplant Infection	Phase 2	2019-09-17
Terminated	The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis Aspergillosis, Cystic Fibrosis	Phase 2	2019-04-03
Terminated	The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory D Asthma, Respiratory Candidiasis, Respiratory Aspergillosis	Phase 2	2018-11-15
Terminated	Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients Respiratory Syncytial Virus Infections	Phase 2	2018-11-05
Completed	A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV C Respiratory Syncytial Virus Infections	Phase 1 / Phase 2	2017-11-14
Completed	A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945 Aspergillosis	Phase 1	2017-10-23
Completed	A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786 Respiratory Syncytial Virus (RSV)	Phase 1	2017-06-21